Sign In
Buy ARWR
$82.00
+0.180 (+0.220%)
At Close: Jun 22, 2026
Here's Why Arrowhead Pharmaceuticals Stock Is Getting Hammered Today
12:18pm, Friday, 02'nd Jul 2021
A paused clinical trial with an important asset wasn't what investors wanted to hear today.
Arrowhead Stock Drops After RNAi Therapeutic Shows Lung Inflammation In Animal Models
08:00am, Friday, 02'nd Jul 2021
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has voluntarily paused the AROENaC1001 Phase 1/2 study evaluating ARO-ENaC for cystic fibrosis. ARO-ENaC is the company's investigational RNA interferen
Horizon Acquires Rights to Arrowhead's RNAi-Based Gout Treatment Candidate
11:35am, Monday, 21'st Jun 2021
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) and Horizon Therapeutics plc (NASDAQ: HZNP) have entered into a global collaboration and license agreement for ARO-XDH for uncontrolled gout. Horizon
Arrowhead: On Target With RNAi Innovation
05:26pm, Monday, 14'th Jun 2021
As it harnesses the powerful RNAi platform coined TRiM, Arrowhead is brewing a robust pipeline of stellar medicines. ARO-AAT is poised to deliver robust clinical outcomes to give the stock more upside
Arrowhead Pharmaceuticals' (ARWR) CEO Christopher Anzalone on Q2 2021 Results - Earnings Call Transcript
12:16am, Wednesday, 05'th May 2021
Arrowhead Pharmaceuticals' (ARWR) CEO Christopher Anzalone on Q2 2021 Results - Earnings Call Transcript
Arrowhead Pharmaceuticals: Partnerships Boost A Bull Case
10:00pm, Wednesday, 28'th Apr 2021
Arrowhead Pharmaceuticals is an inherently innovative biotech. Investigative drug research includes multiple trial phases, requiring great effort, time and significant cash.
Arrowhead's ARO-AAT Treatment Associated With Improved Fibrosis In Patients With Alpha-1 Liver Disease
11:47am, Wednesday, 28'th Apr 2021
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced positive interim 48-week liver biopsy results from the Phase 2 AROAAT2002 study evaluating ARO-AAT for rare genetic liver disease assoc
Arrowhead Pharmaceuticals: RNAi And The Knockdown Effect
11:17pm, Wednesday, 14'th Apr 2021
Arrowhead Pharmaceuticals: RNAi And The Knockdown Effect
Arrowhead: Steady Progress With Lead Indication, Vast Pipeline
11:53am, Friday, 19'th Mar 2021
ARWR is progressing well with its A1AD lead indication. Normally, approval would be in 2023, but accelerated approval is not impossible.
TransCode Therapeutics Starts $29 Million IPO Effort
04:55pm, Sunday, 07'th Mar 2021
TransCode Therapeutics Starts $29 Million IPO Effort
Biogen, Fortinet, Kohl's, Pinterest, Snap and More Friday Afternoon Analyst Calls
11:50am, Friday, 05'th Feb 2021
With the trading day about halfway over, the broad markets were trading sideways into the weekend.
Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q1 2021 Results - Earnings Call Transcript
09:51pm, Thursday, 04'th Feb 2021
Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q1 2021 Results - Earnings Call Transcript
Arrowhead Pharmaceuticals: Q1 Earnings Insights
05:31pm, Thursday, 04'th Feb 2021
Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 566.67% over the past year to ($0.
NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Arrowhead Pharmaceuticals, Inc. (
How Arrowhead Protects Its Intellectual Property
12:17pm, Wednesday, 30'th Dec 2020
ARWR is a leading RNAi therapeutics company with a vast pipeline and a decade-long history of research. Often, companies with a long history of research find themselves unable to protect their Intelle
